Perineural Versus IV Dexmedetomidine as Adjuvant to Quadratus Lamborum Block for Pediatrics Undergoing Pyeloplasty

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

July 10, 2019

Study Completion Date

August 21, 2019

Conditions
Pain, Postoperative
Interventions
DRUG

Quadratus lamborum dexmedetomidine intravenous

Patients will receive quadratus lamborum block on the same surgical side then a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery

DRUG

Quadratus lamborum dexmedetomidine perineural group(

Patients will receive quadratus lamborum block on the same surgical side then1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.

Trial Locations (1)

11566

Ain shams university, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT03885804 - Perineural Versus IV Dexmedetomidine as Adjuvant to Quadratus Lamborum Block for Pediatrics Undergoing Pyeloplasty | Biotech Hunter | Biotech Hunter